ABSTRACT The Niemann-Pick type C1 (NPC1) protein regulates the transport of cholesterol and fatty acids from late endosomes/ lysosomes and has a central role in maintaining lipid homeostasis. NPC1 loss-of-function mutations in humans cause NPC1 disease, a rare autosomal-recessive lipid-storage disorder characterized by progressive and lethal neurodegeneration, as well as liver and lung failure, due to cholesterol infiltration. In humans, genome-wide association studies and post-genome-wide association studies highlight the implication of common variants in NPC1 in adult-onset obesity, body fat mass, and type 2 diabetes. Heterozygous human carriers of rare loss-of-function coding variants in NPC1 display an increased risk of morbid adult obesity. These associations have been confirmed in mice models, showing an important interaction with high-fat diet. In this review, we describe the current state of knowledge for NPC1 variants in relationship to pleiotropic effects on metabolism. We provide evidence that NPC1 gene variations may predispose to common metabolic diseases by modulating steroid hormone synthesis and/or lipid homeostasis. We also propose several important directions of research to further define the complex roles of NPC1 in metabolism. This review emphasizes the contribution of NPC1 to obesity and its metabolic complications. (Endocrine Reviews 39: 192 -220, 2018) 
C
holesterol is an essential structural component of mammalian cell membranes. It affects membrane fluidity, curvature, and the function of associated peripheral and transmembrane proteins. Cholesterol also serves as a signaling molecule that regulates gene expression in diverse metabolic pathways. In certain tissues (e.g., liver, adrenals, gonads, kidney, skin), cholesterol is a precursor for the synthesis of bioactive molecules (e.g., bile acids, steroid hormones, vitamin D) (). Hence, to maintain optimal health and prevent human disease, the concentration of cellular and plasma cholesterol is tightly regulated. Deleterious mutations in genes that regulate cholesterol homeostasis result in severe hereditary disorders, including familial hypercholesterolemia and NiemannPick type C (NPC) disease (, ).
In this review, we describe the current state of knowledge for the NPC intracellular cholesterol transporter  (NPC) gene and protein in relationship to metabolic disease predisposition in mice and humans. We also propose a mechanistic model that may explain how the loss of function/expression of the NPC protein (induced by genetic variations) affects steroid hormone and lipid homeostasis, and thereby increases susceptibility to cardiometabolic diseases in an obesogenic environment. Finally, we propose several important directions of research to further define the complex roles of NPC in metabolism.
Cholesterol Sources, Transport, and Homeostasis in the Organism
In humans,~% (% to %) of ingested dietary cholesterol ( mg/d recommended in adults) is absorbed by enterocytes (). In addition to this exogenous source (diet), endogenous cholesterol synthesis represents a major source of cholesterol in mammalian organisms ( mg produced per day on average). In humans, nearly all cells are capable of synthesizing cholesterol using the condensation of acetyl-coenzyme A (CoA) and acetoacetyl-CoA to form -hydroxy--methylglutaryl-CoA (HMG-CoA) as a precursor of the mevalonate pathway. This synthesis is highly regulated by HMG-CoA reductase, an enzyme that is the target to one of the most commonly used classes of lipid-lowering drugs, the HMG-CoA reductase inhibitors, also known as statins. The liver, small intestine, adrenal cortex, and reproductive organs have the highest rates of de novo cholesterol synthesis in the body. However, unlike the adrenal cortex or gonads that synthesize cholesterol for local use, the liver is considered as the key player in the process of maintaining the whole body's cholesterol homeostasis.
Because cholesterol and cholesterol ester are hydrophobic molecules, these lipids are transported in the blood by lipoproteins. Dietary cholesterol absorbed by enterocytes is mostly converted to cholesterol ester by the acyl-CoA:cholesterol acyltransferase enzyme and incorporated into the triacylglycerolenriched core of chylomicron particles. These particles are secreted into the lymph and transported throughout the blood where their triacylglycerol content is hydrolyzed by the circulating lipoprotein lipase. The resulting chylomicron remnants, whose hydrophobic core is enriched with cholesterol ester particles, are rapidly captured and internalized by hepatocytes.
Forward and reverse cholesterol transport
In hepatocytes, the acyl-CoA:cholesterol acyltransferase catalyzes the esterification of newly synthetized cholesterol with a fatty acid to produce cholesterol esters. These molecules are incorporated into triacylglycerolenriched particles called very-low-density lipoproteins (VLDLs). VLDLs are secreted by the liver into the bloodstream, and, similar to chylomicrons, are acted upon by the lipoprotein lipase, which results in the production of intermediate-density lipoproteins and, eventually, mature low-density lipoproteins (LDLs) enriched with cholesterol ester. LDLs are internalized by cells of peripheral tissues, thereby delivering cholesterol and fatty acids in a process called forward cholesterol transport ().
Conversely, reverse cholesterol transport refers to the process by which the excess of cholesterol is extracted from peripheral cells and carried to steroidogenic tissues (e.g., adrenal cortex or gonads) for steroid hormone production or to the liver for elimination. This transport is mediated by highdensity lipoproteins (HDLs) in a process called reverse cholesterol transport. During this process, the cholesterol ester transfer protein may transfer cholesterol esters from HDLs to VLDLs and intermediatedensity lipoproteins. Once HDLs reach their target tissues, particles bind to the plasma membrane scavenger receptor class B type I receptor that facilitates selective transfer of cholesterol esters from HDLs into the cytoplasm of target cells. In the liver, a fraction of cholesterol acquired by the reverse cholesterol transport pathway serves as the substrate for the production of bile acids. The remaining fraction is secreted along with the bile acids into the intestine in the form of bile and is excreted from the body. Therefore, cellular, tissue, and whole-body cholesterol homeostasis is a dynamic process regulated by complex pathways that function in an orchestrated manner. This results in a complete balance between cholesterol absorption, cholesterol synthesis, cholesterol transport between tissues, and eventually cholesterol excretion in healthy individuals () (Fig. ) .
Role of NPC1 and Niemann-Pick type C2 proteins in intracellular LDL-derived cholesterol transport Receptor-mediated and bulk phase endocytosis of LDLs is the terminal step of forward cholesterol transport. The binding of apolipoprotein B present on the surface of LDLs to the LDL plasma membrane receptor (LDLR) stimulates the internalization of LDL lipoproteins into clathrin-coated vesicles that fuse with acidified early endosomes. The eventual fusion of early endosomes with late endosomes/lysosomes containing an assortment of hydrolytic enzymes results in the ESSENTIAL POINTS · Niemann-Pick C1 (NPC1), a protein coded by the NPC1 gene, locates in the membrane of late endosomes/lysosomes and regulates the efflux of cholesterol and fatty acids from these vesicles · NPC1 loss-of-function mutations cause NPC1 disease, a rare autosomal recessive lipid storage neurodegenerative disorder characterized by an accumulation of cholesterol and other lipids in late endosomes/lysosomes accumulation of degradation products poised for entry into the cytoplasm. The transport of LDL-derived cholesterol and fatty acids from late endosomes/ lysosomes to the cytoplasm and other cellular compartments is mediated by the NPC and NiemannPick type C (NPC) proteins (). In brief, NPC is a soluble protein located in the lumen of the late endosomes/lysosomes that binds and transfers cholesterol to NPC (). NPC, which is associated with the limiting membrane of late endosomes/lysosomes, regulates the efflux of cholesterol and fatty acids from these vesicles () (Fig. ) . It is thought that different proteins interact with NPC to accept cholesterol and facilitate the transport of these lipids to different cellular compartments, including the trans-Golgi network, plasma membrane, and endoplasmic reticulum (-).
Obesity and Complex Metabolic Diseases in the Genomic Era
During the last two decades, researchers have made several important strides in the discovery of new obesity predisposing genes. These advances were the result of a sequential development of new and more powerful genetic tools. For instance, most genes involved in Mendelian disorders were discovered and validated using different natural or genetically engineered mice models, positional cloning, homozygosity mapping, and linkage analysis (). These types of tools allowed the discovery the NPC gene that causes NPC disease (), and the LEP gene whose mutations are associated with monogenic forms of obesity (). Nevertheless, the above-mentioned tools have a very limited power when applied to the discovery of genes involved in complex metabolic traits ().
Complex traits result from the interplay of numerous genetic variants and environmental factors. Examples of complex traits include body mass index (BMI), plasma levels of fasting glucose, fasting insulin, HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), and triglycerides. Metabolic diseases such as common obesity, type  diabetes (TD), metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD) are also categorized as complex disorders. These traits are modestly to highly heritable, with a heritability ranging between % and % (-).
The second major stride in the discovery of obesity genes resulted from the development of genome-wide Figure 1 . Major sources of cholesterol and cholesterol trafficking in the organism. In mammals, cholesterol sources include diet or de novo biosynthesis. Dietary cholesterol (purple arrow) is absorbed by enterocytes and mostly transferred to the liver via chylomicron remnants (yellow arrow). The liver supplies most organs with cholesterol via receptor-mediated endocytosis of LDL-derived cholesterol in a process called forward cholesterol transport (blue arrows). Additionally, most cells are fully capable of de novo cholesterol synthesis to meet their cellular cholesterol requirements (black arrows). Cellular excess of cholesterol is transported in the blood via HDLs to the liver and steroidogenic tissues in a process called reverse cholesterol transport (pink arrows). Ultimately, the liver secretes the excess of cholesterol in the intestine via the bile where it is reabsorbed by enterocytes or excreted in feces (green arrows).
association studies (GWASs). As they are more suited to detect modest genetic effects, GWASs helped discover numerous unsuspected polygenic variants, as well as equally unsuspected physiological and physiopathological mechanisms. Examples of major metabolic genes/loci identified by GWASs include the b cell function-associated HHEX/IDE locus and the zinc transporter SLCA for TD, the gene encoding for the kinase TRIB for blood lipid levels (), and the trans-acting fat mass gene FTO and its subsequently identified cluster of genes (IRX, IRX, and RPGRIPL) for obesity (-).
NPC is another example of an obesity gene identified by GWASs. Indeed, although the gene itself and its function were already known and studied in the context of the Mendelian NPC disease, the association between NPC and polygenic obesity was first identified by a GWAS published in  and performed in adult and children participants of European descent (). Since this publication, NPC became the subject of several post-GWAS studies where several common NPC single nucleotide polymorphisms (SNPs) have been significantly associated with other metabolic traits in both NPC +/+ and NPC +/2 human and mouse subjects (). One follow-up study also investigated the correlation between the severity of NPC mutations and the obesity phenotype by sequencing and analyzing rare variants of NPC +/2 participants (). The results of all of these studies are detailed in "Beyond NPC Disease: Further Evidence of an Effect of NPC Variants on Metabolic Phenotypes" below.
NPC1 Disease
NPC1 gene and protein The human NPC gene and mouse ortholog (Npc) encoding for the NPC protein are localized to a syntenic region on chromosome  (chromosomes q. and A, respectively) (, ). According to the Ensembl database (http://www.ensembl.org) (), up to  transcripts translated into six protein isoforms could be encoded by the human NPC gene (Ensembl version ENSG.). The -amino acid protein is, however, considered as the principal isoform (APPRIS P). According to the same database, the Npc gene encodes a total of five transcripts and a single protein isoform ( amino acids) in mice (Ensembl version ENSMUSG.). NPC is ubiquitously expressed, but the highest levels of expression are detected in the liver, adrenal glands, and lungs (). Results from the GTEx Consortium (https://www.gtexportal.org, query date:  October ) indicate that NPC's most significant expression quantitative trait loci (P , . 3  2 ) are located within . Mb upstream and downstream of the gene itself, and they are highly active in the skin and subcutaneous adipose tissue (). The expression profile of NPC in different tissues, its regulation, and the function of the other NPC isoforms in humans remain poorly described in the literature.
The principal NPC protein has  transmembrane domains and several interesting structural motifs that provide insight into its function (Fig. ) (). Crystal and cryo-electron microscopy structures of the human NPC have recently been described (-). In brief, the N-terminal domain oriented within the lumen of vesicles possesses an unconventional cholesterol-binding domain that accepts cholesterol from the NPC protein (, ). An additional cholesterol-binding domain, referred to as a sterol-sensing domain, is present between the fourth to seventh transmembrane domains and is homologous to three other proteins (HMG-CoA reductase, SCAP, and Patched) that also have an important role in regulating cholesterol metabolism (). A conserved caveolin-binding motif responsible for transferring cholesterol and fatty acids to caveolin that transports these lipids to other cellular compartments is located next to the sterol-sending domain and positioned within the fourth cytoplasmic loop (). Finally, a dileucine motif that facilitates the trafficking of NPC to late endosomes/lysosomes is positioned near the carboxyl terminus and within the cytoplasm ().
In addition to cholesterol and fatty acids transfer, NPC plays a central role in regulating cellular lipid Figure 2 . Proposed mechanism of cholesterol efflux from lysosomes. The endocytosis of LDLs into the cell and resulting accumulation of cholesterol ester in late endosomes/lysosomes (LE/L) initiates a series of events that culminates in cholesterol efflux from these compartments. In brief, lysosomal acid lipase (LAL) catalyzes the hydrolysis of cholesterol esters (CE) to produce unesterified cholesterol (UC) and fatty acids (FA). The NPC2 protein binds UC (but not FAs) and transports cholesterol to the NPC1 protein, which is bound by the amino terminal domain (NTD). Through a mechanism that remains undefined, the NTD transfers UC to a different region of the NPC1 protein called the sterol-sensing domain that is thought to be responsible for cholesterol efflux from lysosomes.
homeostasis by promoting feedback inhibition of the sterol regulatory element-binding protein (SREBP) pathway () (Fig. ) and feed-forward activation of the liver X receptor (LXR) pathway. NPC also downregulates the activity of mTORC, a kinase involved in cell growth and sterol biosynthesis by increasing the expression of SREBPc and SREBP (-). Collectively, these transcription factors and signaling proteins regulate the expression of several hundred genes encoding proteins that participate in diverse metabolic pathways.
Update on NPC1 disease NPC loss-of-function mutations cause NPC disease (OMIM no. ), a rare autosomal recessive lipid storage disorder, biochemically characterized by an accumulation of cholesterol and other lipids in late endosomes/lysosomes (). Patients with NPC disease display a large spectrum of clinical phenotypes. Their life expectancy can vary from a few days to . years. However, the vast majority of patients die between  and  years from complications related to neurologic degeneration and lung failure (). The prevalence of NPC disease was estimated to range between /, to /, cases in Western Europe (). However, a more recent study reports a higher worldwide incidence rate for NPC diseases (~ in , conceptions), whereas the incidence of the late-onset forms is thought to range between /, and /, ().
Approximately % of the cases display mutations in the NPC gene, whereas the remaining cases result from mutations in NPC (, ). 
Clinical features
The symptoms associated with NPC disease are heterogeneous and vary according to the age of onset (early infantile, infantile, juvenile, or adult forms), as well as between individuals of the same age group, which makes clinical diagnosis difficult. Although this disease affects all organs, the accumulation of cholesterol is more pronounced in the viscera and nervous system, giving rise to systemic, neurologic, and psychiatric symptoms: fetal ascites or severe neonatal liver disease and/or lung failure, infantile hypotonia and developmental delay, vertical supranuclear gaze palsy beginning in childhood, followed by progressive ataxia, dysarthria, dystonia, seizures and gelastic cataplexy, psychiatric presentations, mimicking depression, dementia, or schizophrenia, with subtle neurologic signs, beginning in adolescence or adulthood. Enlargement of the liver or spleen can be observed, particularly in early childhood. Dysarthria and dysphagia can become disabling, making oral feeding impossible. Death from inhalation pneumonia usually occurs in the late second or third decade. The different symptoms and the chronology of their appearance have been extensively reviewed elsewhere (, -).
Magnetic resonance imaging of the brain is usually normal until the late stages of the illness, but atrophy of the superior and anterior cerebellar vermis, thinning of the corpus callosum, and mild cerebral atrophy Figure 4 . The SREBP pathway regulates cellular cholesterol metabolism. (a) In sterol-depleted cells, the relative absence of cholesterol and oxysterols located in the endoplasmic reticulum prevents feedback inhibition of the SREBP pathway by inactivating INSIG (retention protein) and activating SCAP (escort protein). SREBP1 and SREBP2 proteins are transported to the Golgi apparatus for proteolytic processing by proteases. The newly generated mature SREBP1 and SREBP2 are then capable of translocating into the nucleus and serving as transcription factors. They increase expression of genes encoding proteins that regulate cellular cholesterol metabolism (e.g., LDLR, NPC1, HMG-CoA synthase, and HMG-CoA reductase). (b) In sterol-enriched cells, the relative abundance of cholesterol and oxysterols located in the endoplasmic reticulum promotes feedback inhibition of the SREBP pathway by activating INSIG and inactivating SCAP to prevent transport of SREBP1 and SREBP2 to the Golgi apparatus for proteolytic processing. (c) In NPC1-deficient cells, cholesterol accumulates in the late endosomes/lysosomes. Because cholesterol is unable to gain access to the endoplasmic reticulum to activate INSIG and inactivate SCAP, impaired feedback inhibition of the SREBP pathway results in increased cholesterol synthesis and receptor-mediated endocytosis of LDLs although the cell has an abundance of cholesterol. ER, endoplasmic reticulum; HMGCR, HMG-CoA reductase; LDLR, LDL receptor; LE/L, late endosome/lysosome; SCAP, SREBP cleavage-activating protein; SRE, sterol regulatory element.
appear sometimes, as well as secondary demyelination in the periatrial white matter. Quantitative magnetic resonance imaging studies in adults with NPC disease showed also gray and white matter abnormalities, resulting in a reduction in total cerebellar volume, correlating to ataxia and ocular motor function but not to duration and severity of disease (). Moreover, one study of magnetic resonance spectroscopy reported improvement in magnetic resonance spectroscopy parameters with miglustat (inhibitor of glucosylceramide synthase) therapy ().
Testing strategies
Owing to the inconsistency and the lack of specificity of disease symptoms between cases, suspicion indexes and diagnosis recommendations have been developed to assist clinicians in diagnosing patients with NPC disease (, ). One of the first and most commonly used NPC laboratory diagnosis tests was filipin staining. For this test, a skin biopsy is collected from individuals, and fibroblasts are grown in culture. Fixed cells are incubated in buffer containing filipin, a dye that binds cholesterol. The observation of an abnormal cholesterol accumulation in cells (fluoresces) under ultraviolet light usually confirms the diagnosis (, ) (Fig. ) . The detection of excessive cholesterol accumulation using filipin staining in blood smear or with alternative reagents has also been proposed (-). The identification of NPC or NPC gene mutations must be performed for patients with highly suspected NPC (based on suspicion indexes or filipin staining) through several DNA sequencing techniques. Detection of the NPC causing mutations in NPC patients also facilitates the screening of NPC mutations in high-risk relatives. Genetic testing should also include analysis of at least one of the parents to better interpret the pathogenicity of the mutation. Prenatal or preimplantation genetic diagnosis requires prior identification of the disease-causing mutations in the family ().
Once NPC-causing mutations have been identified in different subjects, genotype/phenotype correlation tests can be performed to explain the differences in the severity of clinical and biochemical phenotypes observed between cases. For instance, it has been shown that nonsense mutations or nonsynonymous mutations in the sterol-sensing domain of NPC correlate with severe infantile neurologic forms, whereas mutations affecting the cysteine-rich luminal loop are associated to the "variant" biochemical phenotype (i.e., moderate/inconclusive filipin test) (-). However, genotype/phenotype correlation studies are limited for the following reasons: the number of patients is low; a lot of the affected individuals are compound heterozygotes; some biochemical phenotyping methods used (e.g., filipin test) are not precise; and the clinical phenotyping is usually poor ().
Several NPC disease biomarkers (e.g., -ketocholesterol, cholestane-b,a,b-triol, lysosphingomyelin isoforms, bile acid metabolites) have recently been identified and could facilitate the diagnosis of this disease (-). Rapid methods for the detection of these biomarkers have been developed but have not been implemented in the clinical settings yet (-). The latest NPC diagnosis tests were recently reviewed by Vanier et al. () .
Although current diagnostic tests have their limitations, they can lead to a diagnosis in most cases when used in combination. Following clinical orientation, a panel of experts has presently proposed to first assess plasma biomarkers, followed by genetic testing in case of an NPC profile. A filipin test should be mandatory only in the cases in which molecular results remain inconclusive. Mutation analysis is essential in all cases as ultimate confirmation of the diagnosis ().
Current therapy management
Currently, no effective treatment exists for NPC disease. Based on results from a randomized controlled clinical trial () and long-term extension studies (), N-butyldeoxynojirimycin (Miglustat), which is an inhibitor of glucosylceramide synthase, is the only drug approved for the treatment of progressive neurologic manifestations in pediatric and adult patients with NPC in Europe and some other countries, but not in the United States ().
Additionally, symptomatic therapy is usually recommended and consists of the management of seizures, dystonia, and cataplexy, a nocturnal sedative to help disordered sleep, and physical therapy to maintain mobility. Secondary complications are prevented by chest physical therapy with bronchodilation and antibiotic therapy. Regular bowel programs are also set to prevent severe constipation. Swallowing is also monitored to allow placement of a gastrostomy tube when aspiration or nutritional compromise is imminent. Drugs that cause excessive salivation or that may exacerbate seizures by interacting with antiepileptic drugs are avoided as well as alcohol and other drugs that may exacerbate ataxia ().
Metabolic phenotypes of NPC patients
Besides the systemic and neurologic symptoms that characterize NPC disease, patients develop abnormal metabolic phenotypes during the progression of the disorder. NPC patients typically lose weight shortly after onset of neurodegenerative symptoms. Studies have reported abnormal plasma blood profiles for NPC patients, whereby total cholesterol, LDL-C, and HDL-C levels are significantly decreased. In contrast, total triglycerides levels are significantly increased compared with sex-and age-matched healthy controls (, ). Finally, for reasons that remain undefined, transient hepatomegaly and possible progression to hepatic fibrosis and cirrhosis may be an early manifestation of this disease for many NPC patients ().
Animal models of NPC1 disease
Phenotypes associated with loss-of-function mutations in NPC orthologs have been described for different in vivo models, including yeast (), zebrafish (), Drosophila (), dogs (), cats (-), and mice. In these unicellular and complex models, the hallmark of deficient NPC protein function is an accumulation of cellular cholesterol and fatty acids.
To date, five NPC disease mouse models have been identified with either spontaneous or generated mutations and have been used to investigate the pathophysiology of this complex disorder. The mouse models are denoted as Npc spm (), Npc nih (), Npc nmf (), Npc pf/pf (), Npc tm(IT)Dso (), and NPC imagine (). The affected mice display phenotypes similar to humans, including cholesterol accumulation in cells, shortened lifespan, hepatomegaly, ataxia, Purkinje cell loss, neurodegeneration, and other signs of neurologic impairment. Transgenic Npc 2/2 mouse models exclusively expressing the NPC protein in the whole brain, a subtype of brain cells, or in the viscera as well as rescue models for these organs have been described (-). Conversely, wild-type mice (Npc +/+ ) with tissue-specific knockdown of the Npc gene in liver or cerebellar Purkinje cells have also been phenotyped (, ). Taken together, these models have led to a better understanding of NPC protein function.
Metabolic phenotypes of NPC1 disease mouse models An absence of NPC protein function in mouse brain is responsible for weight loss in advanced stages of the disease (). With respect to plasma glucose and lipid levels, Npc 2/2 mice have impaired insulin signaling, increased glucose levels, increased total cholesterol levels, and larger and more heterogeneous HDL particles compared with Npc +/+ mice when fed a basic diet, the phenotypes of which are more pronounced when fed a high-cholesterol diet (, -). In contrast, total triacylglycerol levels are reduced in Npc 2/2 mouse serum (). Npc 2/2 hepatocytes have also been shown to secrete increased amounts of VLDLs possessing an increased cholesterol ester/ triacylglycerol ratio compared with Npc +/+ hepatocytes (). However, some of these results (increased total cholesterol and reduced triacylglycerol) should be considered with caution, because they are discordant with the ones described in human NPC 2/2 subjects and could be due to limited statistical power in some studies.
Conversely, the accumulation of cholesterol in the liver of Npc 2/2 mice is a major disease phenotype in Figure 5 . Fluorescence microscopy of human NPC1
, and NPC1 2/2 fibroblasts. (a) Normal human fibroblasts (NPC1 +/+ ) were grown in basic media and triple stained for NPC1 (red), late endosomes/lysosomes (green), and cholesterol (blue) followed by visualization using deconvolution fluorescence microscopy. (b) Normal human fibroblasts (NPC1
), and NPC1 homozygous fibroblasts (NPC1 2/2 ) were grown in lipoprotein-deficient media enriched with LDL and stained for cholesterol (blue), followed by visualization using conventional fluorescence microscopy. Scale bars, 10 mm.
mice and replicates what was described in NPC patients. Because of this accumulation, Npc 2/2 mice tend to develop liver steatosis and show signs of liver inflammation, damage, and fibrosis (, ).
Collectively, these studies describing phenotypes associated with NPC in both mice and humans underline the plausible role of NPC in the clustering of cardiometabolic traits. However, to better understand the function of NPC, it is important not to restrict the research initiative to the study of compound heterozygous or homozygous affected NPC patients, and to study the full spectrum of genetic variations that could affect the gene. In the following section, we describe the effect of common genetic variants that have a less severe impact than NPC-causing mutations (e.g., SNPs), as well as in heterozygous mice that have only one NPC mutation.
Beyond NPC1 Disease: Further Evidence of an Effect of NPC1 Variants on Metabolic Phenotypes
The most striking phenotypes associated with the development of NPC disease are the neurologic manifestations. Hence, it is expected that NPC gene variants and SNPs should also be associated with neurologic diseases. Consistently, two studies report an association of NPC common variants with Alzheimer disease (, ) and dementia (). Nevertheless, most of the studies exploring the effect of NPC variants in a context other than NPC disease are related to metabolic traits and disorders, which is the focus of this review.
Evidence in humans
Recently, the contribution of two NPC common nonsynonymous SNPs (rs and rs) to polygenic obesity in European populations has placed NPC on the list of genes associated with this common disease (). This association was detected through GWASs, currently one of the most powerful approaches in generating new biological hypotheses. The nonsynonymous coding rs (HR) SNP (minor allele frequency~% in samples of European ancestry of the  Genomes Project) was associated with an increased risk of adult morbid obesity (P = . 3  2 ) (). The rs SNP is also nonsynonymous (IV) and displays strong linkage disequilibrium (r  = ) with rs in Europeans (). Both SNPs are predicted to have a benign effect on NPC protein function according to SIFT (http://sift.jcvi.org/) () and Polyphen- (http://genetics.bwh.harvard. edu/pph/) () in silico tools. However, these computation predictions must be confirmed by functional studies performed in both cellular and animal models using site-directed mutagenesis. The association between rs and adult obesity has been replicated in a consistent direction in several independent European adult cohorts (-). In the Genetic Investigation of ANthropometric Traits (GIANT) consortium (https://www.broadinstitute.org/ collaboration/giant/index.php/GIANT_consortium), the NPC rs "A" obesity allele was associated with an increased risk for overweight [odds ratio (OR) = ., P = .], obesity class I (OR = ., P =  3  2 ), obesity class II (OR = ., P = .), and obesity class III (OR = ., P = .) (). More recently, Sanger and whole-exome sequencing also showed that risk alleles in both rare NPC mutations and in common NPC SNPs were more frequently observed in extremely obese cases than in lean controls (, ). In contrast to what was observed in European studies, the association between NPC rs and adult obesity was not replicated in East Asian and Latino American populations (, ). The absence of association between NPC rs and childhood obesity described in the initial GWAS was confirmed in European and non-European replication studies (, ). If the association between rs and adult BMI has been inconsistent in single study reports of European populations (, , , ), a convincing association was observed in the large-scale GIANT meta-analysis (b = .,
The association between NPC rs and adult BMI was not replicated in Asian populations (, ). Similarly, no association between NPC rs and BMI was observed in young European and non-European populations (, , ). Finally, an association between the NPC rs A obesity risk allele and increased body fat mass was reported in three independent European adult populations (b $ ., P # .) (, , ).
The study of the effect of NPC mutations at the heterozygous state can also be informative, as carriers of a single NPC mutation sometimes display partial manifestations of NPC disease (-). In a recent publication, Liu et al. () examined and described obesity-related phenotypes in a limited number of parents of NPC cases (NPC loss-offunction mutation carriers NPC +/2 participants). In this study, haploinsufficient males had a significantly higher BMI than did their matched controls or than population-based controls. After investigating the severity of several NPC rare mutations identified in severely obese subjects, Liu et al. () also demonstrated that heterozygous carriers of a single rare (minor allele frequency , %) and severe NPC mutation (resulting in .% loss in cholesterol transport ability) had a .-fold higher risk to develop morbid adult obesity, higher waist circumferences, waist-to-hip ratios, and an increased trend of visceral and subcutaneous fat than did carriers of a rare NPC mutation that has a mild/no damaging effect ().
In addition to obesity, two studies in European, non-European, adult, and child populations suggest an association between rs and glycemic parameters, such as fasting insulin (b for the A allele = 2., P = .), insulin sensitivity index (b = 2., P = .), and the homeostatic model assessment of insulin resistance (HOMA-IR; b = ., P = .) (, ). The NPC rs A allele was associated with an increased risk of TD in , adult Danes (OR = ., P = .) (). This association was no longer significant after adjusting for BMI (). Interestingly, when tested among Arabs, no association was observed between the NPC rs SNP and TD whereas another functional polymorphism of NPC, the rs/ MI SNP, was nominally associated with TD in the same study (). Further in silico tests performed in SIFT and Polyphen- revealed that the effect of this amino acid change resulting from the rs SNP is also likely to have only benign consequences on NPC protein function. Because rs, rs, and rs SNPs are in variable linkage disequilibrium in diverse ethnic groups (Supplemental Table ) , the genetic association with metabolic traits may find its origin in a cumulative deleterious functional effect of a coding variant cluster. Our analysis of data from the MetaAnalyses of Glucose and Insulin-related traits Consortium (MAGIC; http://www.magicinvestigators. org/) confirms that the obesity risk alleles of rs, rs, and/or rs SNPs are associated with higher fasting glucose levels, fasting insulin, HOMA-IR, and homeostatic model assessment of b-cell function (Table ) (-). The obesity risk alleles of rs and rs SNPs have also been associated with an increased risk of TD in the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium (http://diagram-consortium.org; OR = . for the three SNPs) (). These associations with TD were no longer significant after adjusting for BMI, thereby suggesting, at least in part, a BMI-dependent effect of NPC on predisposition to TD ().
Two studies have reported an association between NPC and blood lipid levels in Europeans. Borderline associations were found between the rs SNP and total cholesterol, but not LDL-C (, ). Moreover, rs and rs obesity risk alleles were significantly associated with lower HDL-C (b = 2., . # P # . for both SNPs) and higher LDL-C (b = ., P = . for rs) and triglycerides (b = ., P = . for rs) in the Global Lipids Genetics Consortium (GLGC; http://csg.sph.umich.edu/abecasis/ public/lipids/; Table ) (). Modestly powered studies did not show evidence of any association between NPC SNPs and blood lipids in nonEuropean populations (, ).
Data from mice studies
The association between NPC gene variants and anthropometric, glycemic, and lipid traits observed in humans has been elegantly complemented by mouse models. The expression of Npc was negatively correlated with body fat percentage in mice from  different strains (). In the same study, SNPs at the Npc locus were significantly associated with body fat percentage increase after  weeks of exposure to a high-fat/high-sucrose diet through GWASs (). This is an excellent illustration of scientific convergence that has led independent researchers to link NPC and metabolism using hypothesis generating approaches in both humans and rodents. Interestingly, no association between SNPs of the Npc locus and body fat percentage changes was observed when mice were fed with a chow diet only (), which suggests a gene-diet interaction. Other evidence linking Npc genetic variations to altered metabolic traits and demonstrating a gene-diet interaction in rodents arose from the study of Npc heterozygous knockout (Npc +/2 ) mice. These Npc haploinsufficient mice have a similar or slightly increased body weight (% to % increase) compared with control mice (Npc
) when fed a chow diet (-). However, the Npc +/2 mice displayed a significantly increased body weight (% to .% depending on genetic background of the mice) compared with Npc +/+ mice when fed a highfat diet, thereby consistent with a gene-diet interaction (-, , ).
In addition to the high-fat diet, the effect of Npc haploinsufficiency on body weight is also modulated by the age of mice, so that the difference in body weight between Npc +/2 and Npc +/+ fed a high-fat diet is significantly increased for mature adult mice ( to  weeks of age) but not for younger mice (, ). These data fully support the age-dependent effect on obesity observed in humans (). In the case of NPC disease, the accumulation of cholesterol increases over time, which is associated with altered expression in a number of genes and metabolic pathways that parallels the progression of the disease (, ). Hence, it is not surprising that the deleterious effect of NPC genetic variations increases with age in humans and mice (, ).
Similar to what was observed in humans, the study of Npc +/2 mice also showed a gene by sex interaction where only Npc +/2 male mice fed with a high-fat diet showed a significant increase in body weight (). Studies have also determined that Npc +/2 mice fed a high-fat diet are more glucose intolerant and have a significantly increased impaired fasting glycaemia, higher insulin, total cholesterol, HDL-C, and LDL-C levels, as well as higher liver weights compared with Npc +/+ mice fed the same diet (, , ).
"Two studies have reported an association between NPC1 and blood lipid levels in Europeans."
Moreover, fasting blood glucose and HDL/LDLassociated triglycerides were also significantly increased among Npc +/2 mice as compared with Npc +/+ mice, independently of diet (, ). The levels of Npc protein were decreased in liver of Npc +/2 mice compared with Npc +/+ mice fed a high-fat diet (). Additionally, differences in the liver lipid content between Npc +/+ and Npc +/2 mice have also been described. Npc +/2 mice tend to accumulate more cholesterol in the liver and develop hepatic steatosis marked by an increased content of triacylglycerol and fatty acids at a relatively early age (before onset of weight gain or IR development) when fed either a low-fat or a high-fat diet (-).
Based on data from GWASs performed in humans and mice, as well as from candidate gene studies using various Npc haploinsufficient mouse models, a global scheme emerges in which NPC modulates the clustering of cardiometabolic traits, including obesity, TD, dyslipidemia, and NAFLD.
Possible Mechanisms Linking NPC1 to Metabolic Diseases
Prior to suggesting any possible mechanism linking NPC to metabolism, it is important to ensure that the gene of interest is directly causing the observed phenotypes. In this review, we consider NPC as the causal gene and exclude the possibility that other genes in its vicinity (e.g., RIOK and ANKRD) might be responsible for the association with metabolic phenotypes for the following reasons: ) The SNPs reaching GWAS significance when testing the association with obesity are restricted to a linkage disequilibrium block that includes NPC and Corf only. ) No biological evidence relates the other genes surrounding NPC to energy metabolism. ) The genetic changes responsible for the loss of function of NPC in halploinsufficient subjects and knockout mice described in this review are specific to the NPC gene and do not affect other genes. Because NPC and Corf are overlapping in humans, it is impossible to trace back the association signal to one of these two genes based on human genetic studies only. However, the fact that Corf's mouse homolog (HRik) is further upstream of the Npc gene and does not overlap with Npc's coding region strongly suggests that NPC is indeed responsible for the metabolic phenotypes observed in both mice and humans. Few studies have investigated the mechanisms underlying the Npc gene-diet interaction and its effect on body weight. The metabolic phenotyping of wild-type and Npc haploinsufficient mice revealed no differences in nutritional energy consumed, energy expenditure (measured by oxygen consumption, carbon dioxide elimination, locomotor activity, heat production), intestinal fat absorption, and fecal lipid content (and composition) when fed a high-fat diet (, ). Although the exact mechanism remains unknown, these data suggest that NPC does not primarily influence the metabolism and weight gain via neuronal/behavioral mechanisms, but instead by influencing peripheral tissues and organs.
Influence of NPC1 on metabolism via steroid hormones Glucocorticoids (cortisol) and sex hormones (estradiol, progesterone, and testosterone) are synthetized from cholesterol and have been shown to influence metabolism. We hypothesize that NPC genetic variations that impact the expression/function of the encoded NPC protein also affect steroidogenesis, which will consequently modulate various metabolic traits.
Glucocorticoids
Effect of glucocorticoids on metabolism. Cortisol (in humans) and corticosterone (in rodents) are produced as a result of the activation of the hypothalamic-pituitary-adrenal (HPA) axis in response to stress (, ). Their effect on metabolism varies according to the duration of the stressful events. In response to acute stress, glucocorticoids induce hepatic glucose production and influence cardiac frequency and blood pressure as part of the fight or flight reaction. In parallel, vegetative functions such as eating or reproduction are inhibited (, ). The effect of glucocorticoids on metabolism during the acute stress is rapid and extensive; however, this reaction is also brief and does not significantly impact energy homeostasis over the long term. Alternatively, chronic stress reactions result in the activation of the HPA axis as well as other secondary stress management structures such as the brain reward system, which can increase the palatability of food and induce behavior changes such as binge eating (-). These secondary stress management systems escape the control of the energy homoeostasis system and create a disturbed metabolic state causing various metabolic and cardiovascular diseases (). The impact of long-term exposure to glucocorticoids on metabolism is illustrated from an extreme point of view by the cases of patients affected with Cushing syndrome or undergoing long-term corticotherapy, who tend to develop central obesity, fatty liver, hypertension, dyslipidemia, hypertriglyceridemia, IR, and TD.
The increase in plasma glucocorticoid levels modulates the expression of various proteins implicated in the regulation of the energy metabolism (, ), including pro-opiomelanocortin in the hypothalamus (, ), ghrelin in the stomach () and leptin in adipocytes (-). Interestingly, the highest concentration of glucocorticoid receptors in adipose tissue has been detected within visceral fat (), whose expansion is associated with the deleterious metabolic phenotypes, including insulin resistance, dyslipidemia, and NAFLD. Finally, studies indicate that glucocorticoids influence the expression of several genes/proteins implicated in lipid and glucose metabolism, resulting in the inhibition of the glucose transporter  in adipose and skeletal muscles (). In the liver, glucocorticoids increase the activity of phosphoenolpyruvate carboxykinase that regulates both the fatty acid/triacylglycerol cycle through glyceroneogenesis, mobilization of hepatic glucose through gluconeogenesis, and insulin secretion from the pancreas.
Effect of NPC1 gene variations on glucocorticoid levels. LDL-derived cholesterol, the main substrate of NPC, accounts for about a fourth of the total cholesterol in the adrenal cortex, a proportion that is higher than in other steroidogenic tissues (). Because the adrenal cortex requires a relatively large amount of LDL-derived cholesterol to synthesize glucocorticoids, this tissue may be more susceptible to altered cellular cholesterol homeostasis induced by NPC genetic variations.
For evidence in mice, although Npc 2/2 mice display no major disturbances in their circadian rhythm (), their levels of corticosterone are significantly higher than in Npc +/+ mice (). Additionally, our studies indicate that the difference in the concentration of corticosterone between Npc +/+ and Npc +/2 mice when fed a low-fat diet is not significant, whereas Npc +/2 mice fed a high-fat diet have significantly increased concentrations of cortisol compared with Npc +/+ mice fed the same diet (). These observations reinforce the gene-diet interactions we have previously described and support our hypothesis that the effect of NPC genetic variations on metabolism might be mediated by variations in plasma cortisol and corticosterone concentrations.
Several mechanisms may explain why an increase, rather than a decrease, of corticosterone is observed in the context of NPC deficiency. First, although the transport of cholesterol from late endosomes/ lysosomes to the endoplasmic reticulum or plasma membrane is impaired in cells of Npc 2/2 mice, the transport of cholesterol from late endosomes/ lysosomes to the mitochondria for initiation of cortisol synthesis is not mediated by the NPC protein and is consequently not impaired as a result of NPC deficiency (). Second, the numerous disabilities experienced during progression of NPC disease may stimulate the activation of stress pathways, thereby explaining the increased amount of glucocorticoids in affected individuals (). Thus, an accumulation of cholesterol in late endosomes/lysosomes due to NPC deficiency could paradoxically be associated with increased transport of cholesterol to mitochondria, resulting in higher levels of cholesterol in the inner matrix of this organelle. This may increase mitochondrial stress and explain the increased synthesis of cortisol.
For evidence from human studies, no NPC SNP was significantly associated with variations in plasma or saliva levels of cortisol at a GWAS significance threshold (P ,  3  2 ) (-). However, these results are not considered conclusive, as the studies typically had a small size and, hence, a reduced power to detect modest genetic effects.
The effect of NPC genetic variations metabolism via glucocorticoids is suspected to be modulated by various environmental conditions in both mice and humans. This hypothesis is supported by studies indicating that an exposition to high-fat diet downregulates the expression of Npc in mice (a biological interaction) and enhances the hyperglycemic and diabetes-inducing effect of glucocorticoids (-). This hypothesis is also consistent with the observation that the effect of chronic stress on the development of obesity and other metabolic disease phenotypes in mice is enhanced in a context of a high-fat/high-sugar diet ().
The model by which NPC could modulate the risk of metabolic disorders via glucocorticoids is represented in Fig.  .
Sex steroid hormones
Effect of sex steroid hormones on metabolism. Many studies report the effects of sex steroid hormones on metabolism. With respect to estrogens, food intake largely varies across the estrous cycle and during pregnancy in women and mice (). Decreased levels of estradiol after ovariectomy or menopause are associated with weight gain, reduced energy expenditure, increase in adipocytes size, adipose tissue inflammation, and hepatic steatosis. Conversely, lower food intake and increased energy expenditure are observed after estradiol replacement therapy in the context of ovariectomy or menopause. Additionally, mice with global or brain-specific inactivation of estrogen receptor a are obese, hyperphagic, and develop metabolic syndrome [reviewed in (, )]. Estrogens also modulate blood lipid levels. For instance, the beneficial effect of hormonal contraceptive therapy on HDL, LDL, total cholesterol, triacylglycerol levels, metabolic syndrome, and NAFLD in women has long been known (). Conversely, ovariectomy or menopause are accompanied with increased levels of LDL, total cholesterol and triacylglycerol, and a higher risk of TD, obesity, and NAFLD (). Hence, a new estrogen-based therapy that successfully reverts metabolic syndrome and avoids the adverse effects associated with estrogen supplementation (cancer and disturbed reproduction) has recently been tested in mice ().
In addition to being the primary reproductive steroid hormone in males (androgenic effect), testosterone has a strong anabolic effect and regulates energy metabolism. Testosterone deficiency is associated with reduced food intake, increased body fat mass and central obesity, reduced insulin sensitivity, elevated triacylglycerol and cholesterol, low HDL-C, hepatic steatosis, impaired glucose tolerance, TD, and cardiovascular diseases in men and rodents [reviewed in (, , )]. Conversely, testosterone replacement therapy improves IR found in these conditions, in addition to reducing body fat mass (in particular visceral adiposity) and improving glycemic control, cholesterol, and triacylglycerol levels (, , ).
The sex hormone-binding globulin (SHBG), which binds androgens and estrogens with high affinity, regulates the bioavailability of these sex hormones and therefore their effects. Among other factors, the expression of SHBG is regulated by sex steroid hormone levels themselves. It is upregulated by estrogens and downregulated by androgens. In humans, SHBG concentrations have been negatively associated with obesity TD and fatty liver (, ).
Effect of NPC1 gene variations on sex steroid hormones levels. For evidence in mice,~.% and % of the cellular cholesterol in testis and ovaries is provided by LDLs (). Nevertheless, the NPC gene is important for the normal development of reproductive functions. This is illustrated by the fact that both Npc 2/2 affected males and females are sterile and display important histological abnormalities in Figure 6 . Mechanistic model of the effect of NPC1 on metabolic disorders via glucocorticoids. (a) In healthy individuals, chronic stress results in increased levels of glucocorticoids, leading to weight gain and development of metabolic disorders. Because NPC1 is fully functional in these individuals, its effect on glucocorticoid levels is negligible. (b) In NPC1 patients, cholesterol accumulation increases glucocorticoid levels (either directly or by activating the HPA axis). This increase in glucocorticoids could be implicated in onset of some metabolic phenotypes observed in NPC1 patients. (c) In heterozygous carriers of NPC1 loss-of-function mutations or individuals with possibly deleterious NPC1 common gene variants, the combination of environmental factors such as chronic stress and/or high-fat diets/ sedentary lifestyles may lead to higher levels of glucocorticoids and risk of metabolic disorders.
gonads (, ). We hypothesize that NPC deficiency could affect the synthesis and plasma concentrations of sex steroid hormones and subsequently influence metabolism though them.
Studies have shown that plasma concentrations of progesterone are not significantly different between Npc +/+ and Npc 2/2 female mice (, ). In contrast, estradiol levels are reduced in the brain and ovaries of these mice (, ). The administration of b-estradiol to these mice delays the onset of neurologic symptoms () and increases the number and size of follicles in ovaries (, ). Additionally, synthesis of allopregnanolone, a neurologic steroid hormone derived from estradiol, is also impaired in Npc 2/2 mice, and the treatment with allopregnanolone and/or its carrier, the cyclodextrin, significantly improves their neurologic phenotypes, which reinforces the notion that NPC deficiency adversely effects steroid hormones synthesis (, ).
In Npc 2/2 male mice, plasma concentrations of testosterone are lower than in their Npc +/+ counterparts (, ), although this difference was not observed in all studies (). Additionally, a recent study showed that, when fed a high-fat diet, the body weight, fat mass, and adipocyte size of Npc +/2 male mice were significantly higher in their Npc +/+ male counterparts (). The same difference was not observed in Npc +/2 and Npc +/+ female mice, which resulted in a significant gene-sex interaction.
For evidence in humans, several GWASs did not identify NPC as a significant contributor to variations in the levels of sex steroid hormones (testosterone or estradiol) (-). These negative results do not invalidate our sex steroid hormones hypothesis, especially considering the small sample size of these studies, and hence their lack of power to detect modest genetic effects. Additionally, diet, an important modulator of the effect of NPC genetic variations, was not taken into account in these studies, which could have weakened the association results. NPC SNPs have not been shown to influence the levels of SHBG either (, , , , ). Nevertheless, a gene-sex interaction was recently described in a study where the BMI of NPC +/2 men participants was significantly higher than in NPC +/+ men controls. This difference was not significant in women, which mirrors the gene-sex interaction observed in mice ().
Our hypothesis that the NPC gene might influence metabolism by modulating sex steroid hormone production in both mouse and humans is also supported by two other indirect observations. First, dietary fatty acids have been shown to regulate expression of both NPC and the synthesis of these steroid hormones (, ), which together explain the biological gene-environmental interaction that results when Npc +/2 mice are fed a high-fat diet. Second, it is tempting to speculate that the association between NPC SNPs and obesity in adults but not in children or young mice is due to the higher production and/or long-term impregnation of tissues with sex steroid hormones, a phenomenon observed in adolescents and adults only. However, all the obesity GWASs performed in children so far typically had smaller samples sizes than the ones performed in adults. Hence, the difference in the effect of NPC in adults and children should be investigated more thoroughly to exclude the possibility of a false-negative result caused by a lack of power.
In summary, NPC deficiency and haploinsufficiency have been associated with disturbed steroid hormones levels (corticosterone, estradiol, and testosterone) in mice. However, the number of studies reporting these associations is still limited. Further studies are needed to firmly establish the causal relationship between NPC genetic variations, steroid hormones levels, and metabolic disorders in humans and mice.
Influence of NPC1 on metabolism via blood and peripheral tissues lipids Although the accumulation of cholesterol is the most prominent biochemical phenotype in NPC disease, the homeostasis of all lipids and lipoproteins is disturbed by NPC genetic variations. This disturbance is primarily due to the accumulation of not only cholesterol, but also other lipids in late endosomes/ lysosomes. Additionally, because of the strong interplay between the metabolism of cholesterol and fatty acids, the disturbance of one of these two metabolisms impacts the other. For instance, the synthesis of cholesterol requires the use of fatty acids derived from triacylglycerol. As a result, LDL-derived cholesterol deficiency is associated with a higher de novo cholesterol synthesis and, consequently, a reduced triacylglycerol production and a disturbed cholesterol/ triacylglycerol ratio and concentration of circulating lipoproteins (, ).
To date, an increasing number of studies associate abnormal lipoproteins levels to the development of metabolic disorders. For instance, low HDL levels predict the development of insulin resistance, TD, and fatty liver disease in humans (, ), whereas the increase in HDL concentrations in vivo by reconstituted HDL injections is associated with improvement in glucose metabolism (). By inducing reverse cholesterol transport and removing lipids from the liver, the adipose tissue, and the muscles, HDL particles reduce the inflammation and improve insulin sensitivity in those organs. In the pancreas, cholesterol accumulation is known to cause endoplasmic reticulum stress and to impair insulin secretion and induce lipotoxicity and b-cell failure (-). Hence, by depleting the pancreas of its excess cholesterol and lipids, HDL lipoproteins help restore a normal insulin secretion and rescue b-cells from death. The impact of HDL concentrations on glucose metabolism has recently been reviewed by Drew et al. () .
The hypothesis that NPC might influence glucose, lipid, and liver metabolism by modulating blood lipid levels is supported by the fact that the regulation of both intracellular NPC and blood lipids levels is modulated by dietary fats and metabolic status (, ). Additionally, different genomic expression analyses show that NPC deficiency is associated with an important dysregulation of the expression of major genes implicated in intracellular or plasma blood lipids metabolism (e.g., LXRb, SREBP, LDLR, NPC, peroxisome proliferator-activated receptor g, adiponectin receptor, ATP-binding cassette subfamily A member , ATP-binding cassette subfamily G members  and , lipoprotein lipase, hepatic lipase, endothelial lipase) (, , , , ). Accordingly, Npc +/2 mice fed a high-fat diet also had increased expression of genes encoding proteins of the PGC-a/b, LXRa/b, and SREBP- glycolysis and lipogenesis pathways compared with Npc +/+ mice fed the same diet (). Our hypothesis is also supported by the observation that plasma lipoprotein levels vary according to NPC genotype in a non-NPC disease context (human NPC SNPs and mouse Npc haploinsufficiency) as previously mentioned (see "Beyond NPC Disease: Further Evidence of an Effect of NPC Variants on Metabolic Phenotypes," earlier). We have also recently demonstrated that Npc gene dosage influenced lipid levels in peripheral tissues that regulate blood lipids, including the liver (). In adipocytes, we also showed that Npc haploinsufficient mice had decreased activation of hormone sensitive lipase, of triacylglycerol lipolysis, and of glycerol mobilization, compared with Npc +/+ mice when fed a high-fat diet (). When studying fibroblasts, Npc +/2 cells displayed a higher capacity to store neutral lipids (e.g., triacylglycerol and cholesterol) than Npc +/+ fibroblasts (). In brief, the association between NPC genetic variations (deficiency, haploinsufficiency, SNPs) and changes in plasma, as well as peripheral tissue lipids, has been established in different human and mouse studies. Nevertheless, whether a disturbed blood lipid profile is the main cause of the metabolic abnormalities associated with NPC variants still needs to further investigation.
Other possible mechanisms
Another potential mechanism by which NPC deficiency could favor the development of metabolic disorders is through oxidative stress, a well-known biological marker of NPC disease (). Previous studies have shown that reactive oxygen species and cholesterol oxidative product levels are higher in NPC diseases than in other metabolic disorders also characterized by increased oxidative stress, such as obesity, TD, or the metabolic syndrome (, ). Our results also show that Npc +/2 cultured fibroblasts have a higher basal oxidative metabolism of exogenous fatty acids (associated with a reduced oxidative metabolism of endogenous fatty acids) than do Npc +/+ cells. This suggests that the mitochondrial function and the oxidative metabolism are also disturbed in haploinsufficient individuals (). Although it may not be the only cause of these metabolic disorders, the disturbance of the oxidative metabolism induced by NPC variants may predispose to these diseases. In this case, by reducing the efficiency of cholesterol turnover in cells, even modestly, NPC variants could eventually precipitate the onset of this disease in predisposed organisms.
NPC indirectly regulates the activity of mTORC, a kinase involved in fatty acids and sterols biosynthesis and cell growth (, ). Additionally, proteins involved in mTORC's signaling are associated with different obesity and insulin resistance phenotypes in response to dietary fat (). This suggests that the effect of NPC genetic variations and dietary fat on energy metabolism could be partly mediated by mTORC signaling.
Finally, NPC inactivation has been associated with the accumulation of metabolites such as sphingolipids (, ), phospholipids, and glycerophospholipids (), as well as certain lipid-soluble vitamins, including vitamin E (). NPC deficiency also results in altered transport of copper (), defective autophagy (), inflammation and activation of immune response systems (, , , , ), and disturbed Ca + signaling (, ). Hence, one cannot exclude the possibility that NPC's effect is pleiotropic, and that its impact on metabolic diseases results from several of the above-mentioned mechanisms.
Future Directions
Mice studies Because the expression of NPC is ubiquitous, identifying the organs most likely affected by NPC genetic variations responsible for the onset of metabolic abnormalities should be investigated by developing more mice with Npc tissue-specific expression. For example, whether the effect of NPC gene variants are mediated through either altered adipose lipid metabolism will require generating tissue-specific knockdown of the Npc gene in specific tissues. Moreover, one can envision additional genetic manipulations using mouse models to examine whether Npc overexpression results in a lean phenotype and thereby resistance to metabolic diseases (). To date, no mouse model of global Npc overexpression has been described. "This suggests that the effect of NPC1 genetic variations and dietary fat on energy metabolism could be partly mediated by mTORC1 signaling."
Human studies
The NPC gene variants rs, rs, and rs are in stronger linkage disequilibrium in Europeans (Supplemental Table ) . Hence, genetic and functional studies of this haplotype could be performed to reveal a possible cumulative deleterious effect of each variant within the gene cluster. The variable frequency of the rs-rs-rs A-G-A risk haplotype may explain the genetic heterogeneity observed between NPC and metabolic parameters in diverse ethnic groups.
Npc affected mice are sterile (). In humans, most of the NPC patients develop the symptoms and impairments associated with the disease before puberty and die at an early age. The reproductive capacity in the adult forms of NPC disease, which represents a minority of the total diagnosed cases (e.g., only % in France) (), is poorly described in literature. Hence, although it has not been precisely estimated, the fitness (reproductive success) of NPC patients is thought to be very low to null. The frequency of NPC disease causing mutations should therefore remain low in populations as a consequence of purifying selection at each generation (). However, although they are subject to negative selection, these deleterious mutations do not totally disappear in the population because the heterozygotes still transmit them to the next generation (). According to the "thrifty genotype" hypothesis, the carriers of NPC mutations in a heterozygous state, if they harbor a similar phenotype than Npc +/2 mice, may have undergone positive selection during historical periods of erratic food supply because of their higher capacity to store fat. This potential balanced pattern of natural selection makes the NPC gene an interesting candidate for evolutionary genetic studies. The fact that heterozygous individuals harbor higher adiposity than homozygous NPC wild-type () or homozygous mutated individuals (who typically lose weight after the beginning of the neurodegenerative symptoms) may be considered as a case of human overdominance for adiposity. If the overdominance pattern at the NPC locus is formally demonstrated, this gene will join the list of rare examples described in humans to date.
Knowing that most of the deleterious phenotypes associated to NPC inactivation in mice are mainly observed under some specific dietary conditions (high-fat, lithogenic, or high-fat/high-sucrose diets) (-, ), the genotype-diet interactions on metabolic traits in humans should be explored more deeply in large observational/ interventional studies or in families of NPC disease affected individuals. As most of the geneenvironment interactions described in human populations are likely to be false-positive reports, testing a diet-genotype interaction supported by prior work in mouse models will strengthen the level of evidence.
Finally, as both NPC and NPC are implicated in cholesterol and fatty acid export from late endosomes/ lysosomes, and mutations in both of their respective genes cause NPC with undistinguishable clinical phenotypes, the study of the effect of NPC genetic variants on metabolic disorders could be worth investigating.
Complementary human and mice studies
The robust association between NPC SNPs and adult obesity that was initially detected in a GWAS has been confirmed by different replication studies (, -). However, the associations of NPC variants with BMI, TD, lipids levels, and NAFLD still need to be confirmed in other large cohorts and extended to different ethnic groups. Meta-analysis of independent studies and consortia could help reveal more conclusive associations. In mice, deep phenotyping of metabolic parameters for different Npc genotypes (haploinsufficiency, total NPC deficiency, knock-in mice) in different genetic backgrounds may provide new information.
Metabolic traits tend to cluster together. As NPC genetic variants are associated with obesity, the association with other metabolic disorders could develop independently or as a consequence of excess adiposity. Hence, the order of appearance of these diseases according to NPC genotype should be determined in longitudinal human and mouse studies.
NPC SNPs did not reach GWAS significance level in the modestly powered GWASs for sex steroid hormone performed so far (-). Hence, to ascertain whether a modification of steroid hormone levels induced by NPC gene variants mediates the onset of metabolic diseases, measures of these biomarkers in mice (Npc 2/2 and Npc +/2 models) as well as in larger human studies (including in NPC +/2 samples) should be investigated. The measure of the anthropometric and metabolic response to intravenous injections of steroids in wild-type, heterozygotes, and homozygous Npc 2/2 mice could also provide information concerning the role of these molecules.
Finally, a major next step in the study of NPC would be to apply the targeted transethnic sequencing and fine-mapping of the NPC locus in large multiethnic cohorts as well as in large groups of NPC patients and their respective family members. This should enable the identification of new, low-frequency, and potentially deleterious mutations implicated in the development of obesity. As the number of large whole-genome and wholeexome sequencing efforts increases (-), data from large sequencing projects should be jointly used to increase statistical power and specifically analyze rare variants of promising candidate genes such as NPC. The sequencing, fine mapping, and prioritization of genetic variants should be followed by functional characterization of the suspected causal variants by in silico, in vitro, and in vivo experiments. The different approaches used in post-GWAS studies are reviewed elsewhere (, ). Although it has already been successfully used to the study of some NPC mutations (, ), the application of this approach should be extended to all identified and prioritized NPC variants in the future to improve clinical risk stratification and advance the field of personalized medicine.
Clinical relevance and future therapies
NPC1 disease A number of new approaches and molecules have been shown to reduce the accumulation of cholesterol in vitro in NPC disease. However, just a few of these have proven to be effective in vivo. Histone deacetylase inhibitor molecules (e.g., vorinostat) and the -hydroxylpropyl cyclodextrin (HP-b-CD), which solubilize agent lipophilic compounds, can both significantly normalize cholesterol utilization, reduce cholesterol load within tissues, and delay weight loss, motor function impairment, neurodegeneration, and disease progression in mice (, -). It is tempting to speculate that new treatments for NPC disease could be designed using the latest available gene therapy tools, such as adenoviral vectors, for a systemic delivery a functional NPC gene copies in NPC 2/2 patients (). This approach yielded promising results both in vitro and in vivo (-) but has not been implemented in humans yet. Another interesting gene therapy approach would be to use the CRISPR/Cas technology for mutation correction at targeted sites (). Examples of application of this method are limited but encouraging. For instance, the CRISPR/Cas technique successfully corrected STAT mutation in neonatal diabetes mellitus in cultured cells ().
Obesity and its complications
To date, . loci have been associated with BMI, fat distribution, and/or obesity, most of which have been identified by large genome-wide association metaanalyses efforts (, , ). However, so far, only a minority of these loci have been investigated further. In this context, NPC is one of the few Figure 7 . Possible mechanisms linking NPC1 genetic variations to metabolic diseases. NPC1 gene mutations cause NPC1 disease, whereas less severe NPC1 common gene variations cause common metabolic disorders. By modulating the concentration of steroid hormones, as well as blood and peripheral tissues lipid levels (or by other unknown mechanisms), NPC1 genetic variations can also lead various organs, including the brain, pancreas, muscles, adipose tissue, and liver, to modulate body metabolism and energy homeostasis in people not affected with NPC1 disease. This effect on metabolism can eventually result in the onset of metabolic disorders such as obesity, T2D, dyslipidemia, or NAFLD depending on the NPC1 genotype and the environment.
GWAS-identified genes that was the subject of major follow-up studies (, , , ). Because it influences a wide range of metabolic traits, and as some drugs targeting the NPC protein are already available (, ), NPC is one of the very few genes whose study holds considerable promise of a successful application in therapeutic management of human obesity and its complications.
It is very hard to speculate on whether the use of current NPC disease treatments will have any effect on metabolic traits (e.g., BMI-and TD-related phenotypes, blood lipids) of noncarriers of deleterious NPC mutations. This is especially true when considering that the obesity-associated SNPs identified so far have a modest effect size (, ). However, the use of the available NPC disease medications such as Miglustat and HP-b-CD on NPC haploinsufficient subjects is likely to improve their metabolic profile, because these participants lack half of the protein's activity, develop obesity (), and display some mild NPC disease phenotypes (, ). Hence, the currently available NPC disease medications should be tested in Npc +/2 mice. If they are proven to be beneficial in both Npc +/2 mice and NPC +/2 subjects, the application of sequencing techniques will become essential to identify NPC mutation carriers in the general population and provide effective, precise, and personalized treatments based on the genetic profile of each individual.
Conclusion
In this review, we have summarized evidence linking NPC gene variants to metabolic disorders in mice and humans (Supplemental Table ) . We also propose different mechanisms (steroid and/or lipid homeostasis) by which NPC gene variants could predispose to these metabolic diseases (Fig. ) . This review illustrates the synergy of using genetic approaches (hypothesis free and hypothesis driven) in humans and mice to discover new mechanisms explaining the etiology of complex disorders such as obesity, TD, dyslipidemia, and NAFLD. However, some of the explicative models we propose remain speculative, and considerable work remains to be performed to refine the understanding of mechanisms linking NPC to metabolism. We hope that this review, as well as the promising new areas of research investigation that have been proposed, will ultimately improve the health of NPC patients and the general population.
